News

Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million

HealthCare Royalty to purchase royalties from worldwide sales…

4SC Files Marketing Authorisation Application with EMA for Resminostat (Kinselby)

Planegg-Martinsried, Germany, 1 March 2024 – 4SC AG (4SC,…

Rare Disease Day 2024 – Call for greater awareness of X-linked adrenoleukodystrophy and cerebral adrenoleukodystrophy

Barcelona, Spain and Düsseldorf, Germany – 29 February, 2024 –…

BII welcomes twelve new companies to its Venture Lab program

BioInnovation Institute (BII), an international non-profit foundation…

Curve Therapeutics raises £40.5 million to turbocharge discovery platform and advance breakthrough pipeline

Series A financing led by Pfizer Ventures with new investors…

Researchers aim to advance quantum sensing to transform disease diagnosis and prevention

With its unprecedented precision, quantum sensing holds the potential…

Calliditas Year-end report, January – December 2023

OCTOBER – DECEMBER 2023(COMPARED TO OCTOBER – DECEMBER 2022) …

Rejuvenate Biomed’s clinical trial demonstrates the therapeutic potential of RJx-01 in sarcopenia

Cutting-edge therapy shows meaningful improvements in muscle…

We’d love to hear from you

For more information about Optimum Strategic Communications, please get in touch.

© Optimum Strategic Communications.